Caas Capital Management LP Verve Therapeutics, Inc. Transaction History

Caas Capital Management LP

  • $836 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$17.85 - $40.7 $464,100 - $1.06 Million
26,000 New
26,000 $503,000
Q4 2021

Feb 14, 2022
SELL
$31.94 - $54.82 $479,100 - $822,300
-15,000 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$31.92 - $60.25 $478,800 - $903,750
15,000 New
15,000 $904,000

Others Institutions Holding VERV

# of Institutions
186
Shares Held
73.3M
Call Options Held
85K
Put Options Held
215K
View Full List

About Verve Therapeutics, Inc.

VERV Quotes by TradingView
  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $317M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email